SAGE Sage Therapeutics Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: SAGE

Price (delayed)

$42.72

Market cap

$2.55B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$8.98

Enterprise value

$2.4B

Sage Therapeutics is a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain. The Company is pursuing ...

Highlights
The company's debt fell by 34% YoY and by 12% QoQ
The revenue has increased by 22% YoY and by 19% from the previous quarter
SAGE's quick ratio is down by 37% YoY and by 9% QoQ
SAGE's equity is down by 28% YoY and by 9% from the previous quarter
Sector: Healthcare
Industry: Biotechnology
Website: http://www.sagerx.com
Peers: HZNP RGLS ICPT CPRX

Key stats

What are the main financial stats of SAGE
Market
Shares outstanding
59.72M
Market cap
$2.55B
Enterprise value
$2.4B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
2.03
Price to sales (P/S)
329.63
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
312.17
Earnings
Revenue
$7.69M
EBIT
-$532.78M
EBITDA
-$531.66M
Free cash flow
-$460.97M
Per share
EPS
-$8.98
Free cash flow per share
-$7.77
Book value per share
$21.05
Revenue per share
$0.13
TBVPS
$22.87
Balance sheet
Total assets
$1.36B
Total liabilities
$103.85M
Debt
$12.13M
Equity
$1.25B
Working capital
$1.24B
Liquidity
Debt to equity
0.01
Current ratio
13.47
Quick ratio
12.97
Net debt/EBITDA
0.29
Margins
EBITDA margin
-6,917.3%
Gross margin
89.4%
Net margin
-6,931.9%
Operating margin
-7,116.7%
Efficiency
Return on assets
-34.7%
Return on equity
-37%
Return on invested capital
-41.9%
Return on capital employed
-42.4%
Return on sales
-6,931.9%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

SAGE stock price

How has the Sage Therapeutics stock price performed over time
Intraday
-1.32%
1 week
-1.39%
1 month
1.26%
1 year
22.94%
YTD
12.01%
QTD
12.01%

Financial performance

How have Sage Therapeutics's revenue and profit performed over time
Revenue
$7.69M
Gross profit
$6.87M
Operating income
-$546.99M
Net income
-$532.78M
Gross margin
89.4%
Net margin
-6,931.9%
The revenue has increased by 22% YoY and by 19% from the previous quarter
The company's gross profit rose by 20% QoQ and by 19% YoY
Sage Therapeutics's operating income has decreased by 19% YoY and by 5% from the previous quarter
The net income has declined by 16% year-on-year and by 4.4% since the previous quarter

Growth

What is Sage Therapeutics's growth rate over time

Valuation

What is Sage Therapeutics stock price valuation
P/E
N/A
P/B
2.03
P/S
329.63
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
312.17
Sage Therapeutics's EPS has decreased by 15% YoY and by 4.2% from the previous quarter
The P/B is 44% less than the 5-year quarterly average of 3.7 but 37% more than the last 4 quarters average of 1.5
SAGE's equity is down by 28% YoY and by 9% from the previous quarter
SAGE's P/S is 40% below its 5-year quarterly average of 558.0 but 4.8% above its last 4 quarters average of 318.7
The revenue has increased by 22% YoY and by 19% from the previous quarter

Efficiency

How efficient is Sage Therapeutics business performance
Sage Therapeutics's ROE has plunged by 52% YoY and by 13% from the previous quarter
SAGE's ROA is down by 49% year-on-year and by 13% since the previous quarter
The ROIC has contracted by 26% YoY and by 12% from the previous quarter
Sage Therapeutics's ROS has increased by 12% from the previous quarter and by 4.5% YoY

Dividends

What is SAGE's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for SAGE.

Financial health

How did Sage Therapeutics financials performed over time
SAGE's quick ratio is down by 37% YoY and by 9% QoQ
The current ratio has contracted by 36% YoY and by 8% from the previous quarter
The company's debt is 99% lower than its equity
The company's debt fell by 34% YoY and by 12% QoQ
SAGE's equity is down by 28% YoY and by 9% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.